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Key messages
What is already known about this subject?
 ► three phase iii clinical studies (ra-Begin, ra-BeaM, 
ra-BUilD) reported significant reductions in radio-
graphic progression in baricitinib treatment groups 
for up to 1 year of treatment, including in patients 
who were disease-modifying antirheumatic drug 
(DMarD)–naïve or had previously failed to ade-
quately improve on conventional synthetic DMarDs 
(csDMarDs) alone.
What does this study add?
 ► the current analysis extends previous findings, 
demonstrating that treatment with baricitinib 2 and 
4 mg maintains the inhibition of structural joint dam-
age for up to 2 years in patients who completed one 
of the three original studies and entered the long-
term extension study, ra-BeYOnD.
How might this impact on clinical practice?
 ► these data show that baricitinib, as monother-
apy or in combination with csDMarDs, provides 
sustained structural benefits for up to 2 years in a 
broad spectrum of patients with rheumatoid arthritis 
(including DMarD-naïve patients and patients with 
an inadequate response to methotrexate and other 
csDMarDs).
 ► Both 2 and 4 mg doses of baricitinib provided re-
duction on structural damage progression, with the 
most robust evidence seen for the 4 mg dose.
AbstrAct
Objectives to evaluate radiographic progression of 
structural joint damage over 2 years in patients with 
rheumatoid arthritis from baricitinib clinical trials who were 
disease-modifying antirheumatic drug (DMarD)–naïve 
or had an inadequate response to conventional synthetic 
DMarDs (csDMarD-ir).
Methods Patients had completed one of three phase iii 
studies and entered a long-term extension (lte) study, 
continuing on the same baricitinib dose as at originating 
study completion. at 52 weeks, DMarD-naïve patients 
receiving methotrexate (MtX) or combination therapy 
(baricitinib 4 mg+MtX) were switched to baricitinib 4 mg 
monotherapy (±MtX per investigator opinion); MtX-ir 
patients receiving adalimumab were switched to baricitinib 
4 mg on background MtX. at 24 weeks, csDMarD-ir 
patients receiving placebo were switched to baricitinib 
4 mg on background csDMarD. radiographs at baseline, 
year 1 and year 2 were scored using the van der Heijde 
modified total Sharp Score. linear extrapolation was used 
for missing data.
Results Of 2573 randomised patients, 2125 (82.6%) 
entered the lte, of whom 1893 (89.1%) entered this 
analysis. at year 2, progression was significantly lower 
with initial baricitinib (monotherapy or combination 
therapy) versus initial MtX in DMarD-naïve patients 
(proportion with non-progression defined by ≤smallest 
detectable change (SDc): 87.3% baricitinib 4 mg+MtX; 
70.6% MtX; p≤ 0.001). in MtX-ir patients, progression 
with initial baricitinib was significantly lower than with 
initial placebo and similar to initial adalimumab (≤SDc: 
82.7% baricitinib 4 mg; 83.5% adalimumab; 70.6% 
placebo; p≤0.001). in csDMarD-ir patients, significant 
benefit was seen with baricitinib 4 mg (≤SDc: 87.2% vs 
73.2% placebo; p≤0.01).
Conclusions treatment with once-daily baricitinib 
resulted in low rates of radiographic progression for up to 
2 years.
InTROduCTIOn
Rheumatoid arthritis (RA) is a chronic, 
systemic autoimmune disease. Persistent 
inflammation can lead to structural joint 
damage, cartilage loss and erosive bone 
damage, which are associated with disa-
bility and poor patient outcomes.1 2 Current 
recommendations advise early treatment 
with disease-modifying antirheumatic drugs 
(DMARDs) to prevent or delay structural 
progression and the resulting impairments to 
function.3–5
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Baricitinib is an oral, reversible inhibitor of Janus 
kinase (JAK)1 and JAK2, which mediate signal transduc-
tion for a variety of cytokines involved in inflammatory 
conditions, including RA.6 7 Baricitinib is approved for 
the treatment of moderately to severely active RA in 
adults in over 55 countries, including European coun-
tries, Japan and the USA. Three phase III studies previ-
ously evaluated the efficacy of baricitinib in terms of 
radiographic progression in patients with active RA who 
were DMARD-naïve or had an inadequate response (IR) 
to methotrexate (MTX) or to ≥1 conventional synthetic 
(cs)DMARDs.8–10 At weeks 24 and 52, a significant reduc-
tion in radiographic progression was observed with the 
combination of baricitinib 4 mg plus MTX compared 
with MTX alone in DMARD-naïve patients9 and with both 
baricitinib 4 mg and adalimumab on background MTX 
compared with placebo on background MTX in MTX-IR 
patients.10 Both baricitinib 2 mg and 4 mg were associ-
ated with significant inhibition of structural progression 
compared with placebo on background csDMARDs at 24 
weeks in csDMARD-IR patients8 and at 1 year for patients 
who entered into a long-term extension (LTE) study.11 
As RA requires long-term treatment, the objective of the 
current analysis was to extend previous findings, assessing 
radiographic and other efficacy outcomes following up to 
2 years of baricitinib treatment for patients completing 
the originating phase III studies.
MeTHOds
Patients
This analysis included patients who completed 
RA-BEGIN (DMARD-naïve: NCT01711359), RA-BUILD 
(csDMARD-IR: NCT01721057) or RA-BEAM (MTX-IR: 
NCT01710358) and entered into the LTE study RA-BE-
YOND (NCT01885078). The eligibility criteria for the 
originating studies have been previously described.8–10 In 
brief, eligible patients were ≥18 years old with moderately 
to severely active RA as defined by the presence of ≥6 
tender and ≥6 swollen joints (from a 68/66-joint count) 
and a high sensitivity C-reactive protein (hsCRP) level ≥2× 
upper limit of normal (ULN) (≥6 mg/L) for RA-BEAM 
or hsCRP level ≥1.2× ULN (≥3.6 mg/L) for RA-BEGIN 
and RA-BUILD. All patients were biologic DMARD-naïve; 
additionally, patients were csDMARD-naïve or had an 
insufficient response or were intolerant to MTX or ≥1 
csDMARDs.
Patients were eligible for RA-BEYOND if they had 
completed one of the originating studies. Rescue in 
the originating study did not preclude entry to RA-BE-
YOND. Patients were not eligible for participation if they 
were hypersensitive to baricitinib or if they permanently 
discontinued baricitinib during the originating study. 
Patients were also excluded if they had developed any 
significant medical issues or uncontrolled laboratory 
abnormalities during the originating study that were, in 
the opinion of the investigator, an unacceptable risk to 
the patient.
study design
RA-BEYOND is an ongoing (study duration up to 7 years) 
phase III multicentre LTE of the safety and efficacy of 
baricitinib in patients who had completed prior baric-
itinib phase II and phase III clinical trials. The designs of 
the originating studies have been previously published8–10 
(see figure 1 and online supplementary methods). 
Patients receiving blinded baricitinib at the conclusion 
of an originating study remained on that dose (2 mg or 
4 mg, once daily) in RA-BEYOND in a manner blinded 
to the patient and investigator. In addition, the design of 
RA-BEYOND included a randomised, blinded substudy 
on dose step-down from baricitinib 4 mg to 2 mg in 
patients who had achieved sustained disease control on 
the higher dose (see online supplementary methods for 
more detail).12
At 52 weeks in the DMARD-naïve study (at entry to the 
LTE), patients receiving MTX or baricitinib 4 mg plus 
MTX were switched to baricitinib 4 mg monotherapy 
but could be prescribed MTX or other csDMARDs at the 
discretion of the investigator at any time point during 
the LTE. Patients who initiated or increased csDMARDs 
above the doses used in the randomised, controlled phase 
of the study were captured through an Interactive Web 
Response System as rescued. At 52 weeks in the MTX-IR 
study (at entry to the LTE), patients receiving adalim-
umab on background MTX were switched to baricitinib 
4 mg plus MTX. At 24 weeks in the csDMARD-IR study 
(at entry to the LTE), patients receiving placebo were 
switched to baricitinib 4 mg on background csDMARDs. 
Patients from this study who were rescued from barici-
tinib 2 mg to 4 mg received baricitinib 4 mg in the LTE; 
patients who received baricitinib 2 mg in the originating 
study without rescue continued on 2 mg in the LTE. 
In the LTE, csDMARDs could be initiated and dosages 
increased as rescue therapy for patients from the MTX-IR 
and csDMARD-IR studies who had a Clinical Disease 
Activity Index score >10 at or after 3 months following 
enrolment into the LTE; patients with normal renal func-
tion on baricitinib 2 mg could be rescued to 4 mg. Use of 
biologics was prohibited in the LTE.
Radiographic progression
Radiographic progression of structural joint damage 
was determined by the change from baseline in the van 
der Heijde modified Total Sharp Score (mTSS)13 and 
its subcomponents, the erosion score and joint space 
narrowing score. In addition, the proportion of patients 
showing no progression was determined based on 
change from baseline mTSS (ΔmTSS) of the originating 
study, using thresholds of 0, 0.5 or the smallest detectable 
change (SDC).14
To derive the mTSS, radiographs of the hands/wrists 
and feet were scored, quantifying the extent of bone 
erosion and joint space narrowing for 44 and 42 joints, 
respectively, with higher scores representing greater 
damage. Radiographs were scored by two central readers 
blinded to chronologic order, patient identity and 
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Figure 1 Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Data are up to 
2 years on treatment, corresponding to 100 weeks in RA-BEGIN and RA-BEAM or 96 weeks in RA-BUILD due to the different 
duration and visit structures of the originating studies. Patients from RA-BEGIN switched to baricitinib 4 mg at entry to RA-
BEYOND at week 52; during RA-BEYOND, MTX or other csDMARDs could be prescribed at any time point at the discretion 
of the investigators. Patients from RA-BEAM originally randomised to placebo were switched to baricitinib 4 mg at rescue or 
week 24; patients randomised to adalimumab were switched to baricitinib 4 mg at rescue or entry to RA-BEYOND at week 
52. Patients in RA-BUILD initially randomised to placebo switched to baricitinib 4 mg at rescue or week 24 at entry to RA-
BEYOND. Patients who remained on baricitinib 2 mg in RA-BUILD continued on 2 mg in RA-BEYOND; those rescued from 
baricitinib 2 mg to 4 mg in RA-BUILD received baricitinib 4 mg in RA-BEYOND. Background csDMARDs were permitted in 
RA-BUILD and RA-BEAM. csDMARD, conventional synthetic DMARD; DMARD, disease-modifying antirheumatic drug; IR, 
inadequate responder; MTX, methotrexate; N, number of patients randomised and treated; Q2W, once every 2 weeks; QD, 
once daily; RA, rheumatoid arthritis.
treatment group. The mean score obtained between 
the two readers was used in the analysis. Baseline initial 
radiographs taken during the originating study served as 
the baseline radiographs for comparison throughout the 
LTE. Results comprise radiographs analysed in the same 
read campaign that included baseline, 1 year, and either 
2-year or early termination time points. Radiographs 
were taken at study discontinuation if the most recent 
radiograph was more than 12 weeks earlier.
Clinical efficacy outcomes
The proportion of patients achieving specific thresh-
olds in clinical efficacy measures was assessed at 12, 24 
(DMARD-naïve, MTX-IR and csDMARD-IR studies) and 
52 weeks (DMARD-naïve and MTX-IR studies) during 
the originating studies and every 12 weeks in the LTE up 
to 2 years. The outcomes examined included a Simplified 
Disease Activity Index (SDAI) score of ≤11 and a minimal 
clinically important difference (MCID) of at least 0.22 
decrease from baseline on the Health Assessment Ques-
tionnaire–Disability Index (HAQ-DI).
statistical analyses
Randomised patients who received at least one dose of 
the assigned study drug were included in the analyses. 
The analysis population for radiographic progression 
comprised patients with radiographs at baseline and at 
least one radiograph from the LTE after the 1 year radio-
graph. A mixed model for repeated measures (MMRM) 
was used to analyse continuous variables with treatment, 
visit and treatment-by-visit-interaction as fixed categor-
ical effects and baseline and baseline-by-visit-interaction 
as fixed continuous effects. A logistic regression model 
with treatment included as a factor was used to analyse 
categorical variables (proportion of patients with no 
radiographic progression (ie, the proportion of patients 
meeting one of the thresholds set for ΔmTSS ≤0, ≤0.5 or 
≤SDC), SDAI, HAQ-DI). The SDC was computed based 
on week 0 to year 1 and to year 2 changes in mTSS scores 
assigned by two blinded readers.14
Structural data observed after rescue or step-down 
were included in the analysis, and patients were anal-
ysed based on original randomisation. Linear extrapo-
lation15–20 was used to impute missing scores at 2 years 
for patients who discontinued the study early and had 
radiographs available at 1 year and the early termination 
visit. The remaining missing scores at 2 years, for which 
linear extrapolation was not possible due to missing 
radiographs, were handled by the MMRM analysis (for 
continuous variables) or by exclusion of patients from 
the analysis (for the categorical variable of radiographic 
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Figure 2 Patient disposition after 2 years of treatment. 
Summary of the analysis population in RA-BEYOND for 
patients originally completing (A) RA-BEGIN, (B) RA-BEAM 
or (C) RA-BUILD. Disposition is shown for up to 2 years 
on treatment, corresponding to a total of 100 weeks in 
RA-BEGIN and RA-BEAM (52 weeks in the originating 
study plus 48 weeks in RA-BEYOND) and 96 weeks in 
RA-BUILD (24 weeks in originating study plus 72 weeks 
in RA-BEYOND) due to the different durations and visit 
structures of the originating studies. Patients on placebo, 
MTX or adalimumab in the originating studies switched to 
baricitinib 4 mg at rescue or at 24 or 52 weeks, as detailed in 
the Study design section. The analysis populations in each 
group were the patients with radiographic assessments at 
baseline of the originating study and at least one radiograph 
from RA-BEYOND after the 1-year radiograph. LTE, long-
term extension; MTX, methotrexate; QD, once daily; RA, 
rheumatoid arthritis.
non-progression). The between-group comparisons were 
assessed with a significance level of 0.05 (two-sided). For 
SDAI and HAQ-DI data, non-responder imputation was 
applied after discontinuation of study or study drug. The 
data cut-off date was September 1, 2016.
ResulTs
Patient disposition
Patient disposition is shown in figure 2 according to the 
treatment groups in the originating studies. Overall, 2573 
patients were randomised, and the majority (N=2125; 
82.6%) entered the LTE. Of these, the requisite radi-
ographic assessments were available for 1893 patients 
(89.1%; RA-BEGIN (DMARD-naive): N=410, RA-BEAM 
(MTX-IR): N=1009, RA-BUILD (csDMARD-IR): N=474) 
for this analysis. The proportions of patients from 
RA-BEGIN or RA-BEAM in the analysis population of the 
LTE completing through 48 weeks (ie, 100 weeks, or 2 
years, of treatment; figure 2A,B) and from RA-BUILD 
completing through 72 weeks (ie, 96 weeks, or 2 years, 
of treatment; figure 2C) were high (>94%) and similar 
across the original treatment groups in each study. 
Overall, 13 (3.2%), 37 (3.7%) and 13 (2.7%) patients 
from the DMARD-naïve, MTX-IR and csDMARD-IR 
studies, respectively, discontinued from the study during 
the analysis period in the LTE. In general, there were no 
major differences in discontinuations across the original 
treatment arms. The most common reason for discontin-
uation was an adverse event (DMARD-naive: n=8 of 13 
discontinuations, 62%; MTX-IR: n=20 of 37 discontinu-
ations, 54.1%; csDMARD-IR: n=6 of 13 discontinuations, 
46.2%). For patients discontinuing early, linear extrap-
olation was applied (when possible) at year 2 for mTSS 
(0.0%–6.6% of patients per group; see online supple-
mentary table 1).
The demographic characteristics of the 2-year analysis 
populations in the LTE were generally similar across the 
treatment groups at baseline of the originating studies: 
the majority of patients were white (>55%) and female 
(>70%), with a mean age range of 47.5 to 52.9 years 
(table 1). Clinical characteristics at baseline were similar 
across the treatment groups of the originating studies, 
but some characteristics differed across studies due to 
differences in the eligibility criteria of the originating 
studies (table 1).
structural progression
Across the patient populations, treatment with baricitinib 
was associated with low progression of structural joint 
damage. For the DMARD-naïve patients originating in 
RA-BEGIN, those on initial baricitinib 4 mg plus MTX 
showed significantly smaller mean changes from baseline 
mTSS and erosion scores than patients on initial MTX at 
both years 1 and 2 (p≤0.001; figure 3A); those on initial 
baricitinib 4 mg monotherapy also had significantly 
fewer erosions than patients on initial MTX (p≤0.05). 
In agreement with these findings, a greater proportion 
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Figure 3 Inhibition of radiographic progression of structural joint damage at year 1 and year 2 by original randomisation. The 
LS mean change from baseline (±SEM) in structural joint damage evaluated using (A) mTSS, (B) ES and (C) JSN for patients in 
RA-BEYOND originally completing RA-BEGIN, RA-BEAM or RA-BUILD. Time points represent time from randomisation in the 
originating studies. Indicated treatment groups are according to randomisation in the originating study (‘initial’ denotes initial 
randomised treatment group). Patients on PBO, MTX or ADA in the originating studies switched to baricitinib 4 mg at rescue 
or at 24 weeks (PBO; single arrow) or 52 weeks (MTX and ADA; double arrow) as detailed in the Study design section. Tables 
represent the number of patients for whom data were available for each time point and study. Comparisons were analysed 
using a mixed model for repeated measures. Missing scores at 2 years were imputed using linear extrapolation based on data 
collected between 1 and 2 years. SE of the mean *p≤0.05, **p≤0.01, ***p≤0.001 baricitinib 4 mg vs PBO (RA-BEAM; RA-BUILD) 
or MTX (RA-BEGIN); +p≤0.05, ++p≤0.01, +++p≤0.001 ADA vs PBO (RA-BEAM); ‡p≤0.05 baricitinib 4 mg vs baricitinib 4 mg plus 
MTX (RA-BEGIN). ADA, adalimumab; Bari, baricitinib; ES, erosion score; JSN, joint space narrowing; LS, least squares; mTSS, 
modified Total Sharp Score; MTX, methotrexate; PBO, placebo; RA, rheumatoid arthritis.
of patients who had received initial baricitinib therapies 
in the DMARD-naïve study had no radiographic progres-
sion compared with patients who had received initial 
MTX monotherapy. These differences reached statistical 
significance at both years 1 and 2 for the initial baric-
itinib 4 mg plus MTX group when any of the thresholds 
were used (figure 4; see online supplementary table 2) 
and for the baricitinib 4 mg monotherapy group when 
either the ΔmTSS ≤0 or ΔmTSS ≤0.5 thresholds were 
used (see online supplementary table 2). For MTX-IR 
patients originating in RA-BEAM, those on initial baric-
itinib 4 mg had statistically significantly lower radio-
graphic progression at years 1 and 2 than patients on 
initial placebo, and similar progression to patients on 
initial adalimumab (figure 3B). Both the baricitinib 4 
mg and initial adalimumab groups also showed similar 
proportions of patients with mTSS nonprogression using 
any of the thresholds, which were statistically significantly 
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Figure 4 Patient-level radiographic progression of structural joint damage at year 1 and year 2 by original randomisation. 
Panels show radiographic progression in structural joint damage evaluated using cumulative percentile change in the modified 
Total Sharp Score (mTSS) from baseline at year 1 and year 2 for patients in RA-BEYOND originally completing (A) RA-BEGIN, 
(B) RA-BEAM or (C) RA-BUILD. Each point represents an individual patient. Indicated treatment groups are according to 
randomisation in the originating study (‘initial’ denotes initial randomised treatment group). Inserted tables show n and 
percentage non-progression as defined by ≤SDC. Patients on placebo, MTX or adalimumab in the originating studies switched 
to baricitinib 4 mg at rescue or at 24 or 52 weeks, as detailed in the Study design section. **p≤0.01, ***p≤0.001 vs placebo 
(RA-BEAM; RA-BUILD) or MTX (RA-BEGIN). Δ, change from baseline; mTSS, modified Total Sharp Score; MTX, methotrexate; 
n, number of patients meeting threshold; N, number of patients with non-missing baseline and ≥1 non-missing post-baseline 
mTSS data; N-obs, number of patients included in analysis; RA, rheumatoid arthritis; SDC, smallest detectable change.
higher than the proportion of patients showing no 
radiographic progression in the initial placebo group 
at both years 1 and 2 (figure 4; online supplementary 
table 2). For csDMARD-IR patients who had completed 
RA-BUILD, those on initial baricitinib 4 mg showed 
significantly smaller mean changes in mTSS and erosions 
(p≤0.05; figure 2C) and a greater proportion showed no 
radiographic progression (figure 4; online supplemen-
tary table 2) compared with patients on initial placebo at 
years 1 and 2 (p≤0.05; figure 2C). Progression with initial 
baricitinib 2 mg was numerically lower than with initial 
placebo (figure 3C); the proportion of patients showing 
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Figure 5 Proportion of patients (NRI) on baricitinib achieving SDAI ≤11 and meeting or exceeding HAQ-DI MCID (≥0.22) up to 
year 2 by original randomisation groups. Baseline in the originating study was used in the calculation of response. Time points 
represent time from randomisation in originating study, with year 1 and year 2 corresponding respectively to week 52 and week 
100 for RA-BEGIN and RA-BEAM and to week 48 and week 96 for RA-BUILD due to the different durations and visit structures 
of the originating studies. Time points between year 1 and year 2 are in 12-week intervals. Dotted lines indicate entry into the 
long-term extension study. Analyses exclude patients who were rescued in the originating studies. NRI was applied without 
regard to rescue status in RA-BEYOND. Data after patients stepped down to baricitinib 2 mg were imputed using the response 
rate of the patients who continued with baricitinib 4 mg. ‘Initial’ denotes initial randomised treatment group. Bari, baricitinib; 
HAQ-DI, Health Assessment Questionnaire–Disability Index; MCID, minimally clinically important difference; N, number of 
patients not rescued in the originating study, who continued on the same dose in RA-BEYOND and entered RA-BEYOND 96 
weeks before the cut-off date; NRI, non-responder imputation; SDAI, Simplified Disease Activity Index; RA, rheumatoid arthritis.
no mTSS progression was also higher in the baricitinib 
2 mg group compared with the placebo group at both 1 
and 2 years, but these differences did not reach statistical 
significance.
For all treatment groups, lower rates of change in mTSS 
were observed between years 1 and 2 (when all patients 
were on baricitinib therapies) than between baseline and 
year 1 (figure 3). Patients originally randomised to MTX 
or placebo exhibited greater increases in mTSS between 
years 1 and 2 (0.35±0.10 in RA-BEGIN; 0.56±0.09 in 
RA-BEAM; 0.33±0.09 in RA-BUILD) than those originally 
randomised to baricitinib treatment groups (0.21±0.01 
and 0.24±0.09 for baricitinib 4 mg and baricitinib 4 mg 
plus MTX, respectively, in RA-BEGIN; 0.32±0.08 for 
baricitinib 4 mg in RA-BEAM; 0.28±0.09 and 0.24±0.09 
for 2 and 4 mg, respectively, in RA-BUILD) (figure 3). 
Individual patient-level changes in radiographic progres-
sion from baseline were in accordance with these data at 
years 1 and 2 (figure 4).
Clinical efficacy
The majority (>60%) of patients across studies receiving 
baricitinib treatment achieved SDAI ≤11 at entry into the 
LTE study RA-BEYOND (figure 5A), which was sustained 
for up to 2 years of treatment. Similarly, the majority 
of patients on baricitinib 4 mg across the studies had 
functional benefit from treatment, with approximately 
75% of patients on baricitinib who met or exceeded the 
HAQ-DI MCID (≥0.22) by week 12 in the originating 
studies (figure 5B). More than 60% of patients across 
studies met or exceeded the HAQ-DI MCID (≥0.22) at 
both years 1 and 2. The patients receiving the 2 mg dose 
through 2 years showed similar results to those receiving 
the 4 mg dose in terms of both SDAI ≤11 and HAQ-DI 
MCID (≥0.22) response.
dIsCussIOn
The current analysis is a report on radiographic 
outcomes in the LTE study, RA-BEYOND, including 
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patients from three studies with active RA who were 
either DMARD-naïve or had an inadequate response to 
MTX or ≥1 csDMARDs. The key finding is that baric-
itinib inhibited structural progression for up to 2 years of 
treatment, as assessed by total mTSS, erosions and joint 
space narrowing. Patients initially started on MTX or 
placebo exhibited significantly larger changes from base-
line mTSS than those started on baricitinib 4 mg, either 
alone or in combination with MTX, with a higher propor-
tion of patients on initial baricitinib therapies exhibiting 
non-progression at years 1 and 2. Further, patients on 
initial baricitinib therapies exhibited minimal changes 
in mTSS between years 1 and 2 compared with those on 
initial placebo or MTX, indicating that the inhibition 
of structural progression associated with initial baric-
itinib persisted during the second year of treatment. In 
MTX-IR patients completing RA-BEAM, radiographic 
outcomes at 1 year were similar between patients initially 
randomised to baricitinib 4 mg and adalimumab and 
remained similar at 2 years (ie, 1 year following the 
switch of initial adalimumab-treated patients to baric-
itinib 4 mg). These data are consistent with, and further 
extend, the original findings of the three studies, which 
reported significant reductions in radiographic progres-
sion in the baricitinib treatment groups at the end of 
the randomised study periods8–10 and at 1 year for the 
patients who had completed the csDMARD-IR study 
RA-BUILD and entered the LTE.11 Collectively, the data 
show that baricitinib, as a monotherapy or in combina-
tion with MTX/csDMARDs, provides sustained structural 
benefits in many patients with active RA, including those 
who have previously failed to adequately improve on 
MTX or other csDMARDs. Further, the data indicate that 
patients originally randomised to placebo or MTX and 
then switched to baricitinib 4 mg at 24 weeks continue to 
exhibit worse structural progression than patients origi-
nally randomised to baricitinib, even after 2 years of treat-
ment, indicating that early intervention with baricitinib 
therapies is beneficial in the long term.
For the current analysis, radiographs at baseline and 
1 year were reread during scoring of the year 2 radio-
graphs. Consistent with previous studies which showed 
statistically significant structural benefit of baricitinib 2 
mg and 4 mg at 24 and 52 weeks,8 11 the current study 
demonstrates significant benefit with initial baricitinib 4 
mg in this population with up to 2 years of treatment. 
In addition, numerically greater reductions in the mean 
change from baseline mTSS and a higher proportion of 
patients showing no mTSS progression were observed 
in patients treated with baricitinib 2 mg compared with 
those on initial placebo who, at years 1 and 2, would 
have been treated with baricitinib 4 mg for 24 and 72 
weeks, respectively. Collectively, the data indicate that 
both doses are effective at reducing structural progres-
sion with the best outcomes observed when treatment 
was started sooner and a more robust structural benefit 
achieved with baricitinib 4 mg.
In keeping with the radiographic progression find-
ings, the majority of patients across the three originating 
studies receiving baricitinib therapies achieved SDAI 
≤11 and HAQ-DI MCID by entry to the LTE, and this 
was maintained for up to 2 years on treatment. These 
data suggest that the sustained improvements in disease 
activity observed with long-term baricitinib treatment 
were associated with structural benefit and improved 
function. Safety was not examined in the current report 
as separate assessments of the safety of long-term baric-
itinib treatment have been conducted recently, which 
reported no significant new safety signals during the 
LTE up to 288 weeks.11 21 22 Notably, a recent compre-
hensive safety report has been published, which used 
the same data cut-off date as the current paper and large 
integrated data analysis sets from the baricitinib clinical 
programme.22 Across anaysis sets, infections were the 
most common adverse events reported in the baricitinib 
groups, but no notable differences were observed across 
treatment groups in the rates of serious adverse events 
including deaths, permanent discontinuations due to 
adverse events, malignancies, major adverse cardiovas-
cular events and serious infections.22 Collectively, the 
data indicate that baricitinib treatment has a long-term 
clinical benefit with an acceptable safety profile.
There are some limitations to this analysis. Although 
this study included a large patient population, repre-
senting both DMARD-naïve and csDMARD-IR patients 
with active RA, this analysis included patients with varying 
treatment regimens and exposures to baricitinib due to 
differences in the designs of the three originating studies 
and to rescue and taper during the LTE. The study design 
did not permit comparison between active treatments 
and doses across studies. In addition, the LTE was open 
label, and patients were aware that they were receiving 
baricitinib. However, both patient and investigator were 
blinded to original randomised treatment assignments 
and the dose of baricitinib. Further, all radiographs were 
scored by two central readers who were blinded to all 
clinical information.
In conclusion, treatment with once-daily baricitinib was 
associated with low rates of radiographic progression for 
up to 2 years of treatment. Patients on initial baricitinib 
showed significantly less progression than those starting 
with placebo or MTX then switched to baricitinib, and 
comparable progression with those starting with adali-
mumab then switched to baricitinib. These differences 
in the level of progression were observed at both years 1 
and 2, indicating a persistent structural benefit with long-
term baricitinib treatment. For csDMARD-IR patients, 
treatment with baricitinib 2 mg and 4 mg was associated 
with reduced radiographic progression compared with 
initial placebo, with baricitinib 4 mg providing more 
robust evidence than the 2 mg dose.
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